ATE250133T1 - Verktorvermittelte genominsertion und expression von dna in bcg - Google Patents

Verktorvermittelte genominsertion und expression von dna in bcg

Info

Publication number
ATE250133T1
ATE250133T1 AT90909981T AT90909981T ATE250133T1 AT E250133 T1 ATE250133 T1 AT E250133T1 AT 90909981 T AT90909981 T AT 90909981T AT 90909981 T AT90909981 T AT 90909981T AT E250133 T1 ATE250133 T1 AT E250133T1
Authority
AT
Austria
Prior art keywords
dna
ctor
bcg
expression
dna encoding
Prior art date
Application number
AT90909981T
Other languages
English (en)
Inventor
Richard A Young
Anna Aldovini
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE250133T1 publication Critical patent/ATE250133T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT90909981T 1989-06-19 1990-06-18 Verktorvermittelte genominsertion und expression von dna in bcg ATE250133T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36789489A 1989-06-19 1989-06-19
PCT/US1990/003451 WO1990015873A1 (en) 1989-06-19 1990-06-18 Vector-mediated genomic insertion and expression of dna in bcg

Publications (1)

Publication Number Publication Date
ATE250133T1 true ATE250133T1 (de) 2003-10-15

Family

ID=23449053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909981T ATE250133T1 (de) 1989-06-19 1990-06-18 Verktorvermittelte genominsertion und expression von dna in bcg

Country Status (7)

Country Link
EP (1) EP0478664B1 (de)
JP (1) JPH04506297A (de)
AT (1) ATE250133T1 (de)
AU (1) AU5848090A (de)
CA (1) CA2063414A1 (de)
DE (1) DE69034100T2 (de)
WO (1) WO1990015873A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
EP0587765A4 (de) * 1991-06-06 1994-11-02 Medimmune Inc Induktion der immunantwort gegen das tetanustoxin durch verarbeitung von mycobakterien, die das tetanustoxin oder fragmente davon exprimieren.
EP0590027A4 (de) * 1991-06-13 1994-10-19 Einstein Coll Med Mutationen in mycobakterien durch geneinbau.
US6566121B1 (en) * 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
EP0521220A1 (de) * 1991-06-14 1993-01-07 Institut Pasteur Immunogene rekombinante Actinomycetale
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
ES2171454T3 (es) * 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
JPH09505588A (ja) 1993-11-23 1997-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多くの細胞外生成物及びそれらの製造法並びに使用
DE4425382C2 (de) * 1994-07-19 1997-08-14 Univ Hohenheim Salmonella-Lebendimpfstoff
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
NZ538399A (en) 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
CA2396384A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
KR20030074787A (ko) 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
EP1535627B1 (de) * 2002-08-16 2008-07-09 Japan Science and Technology Agency Rekombinante bcg-vakzine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
JPH04506297A (ja) 1992-11-05
WO1990015873A1 (en) 1990-12-27
CA2063414A1 (en) 1990-12-20
EP0478664A1 (de) 1992-04-08
DE69034100T2 (de) 2004-06-09
DE69034100D1 (de) 2003-10-23
EP0478664B1 (de) 2003-09-17
AU5848090A (en) 1991-01-08

Similar Documents

Publication Publication Date Title
ATE250133T1 (de) Verktorvermittelte genominsertion und expression von dna in bcg
ATE256730T1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
ATE133681T1 (de) Mykobakterielle rekombinanten und peptide
NO885664D0 (no) Polypeptider og derivater derav, samt anvendelse i farmasoeytiske og diagnostiske preparater.
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
ATE49233T1 (de) Vektoren zur transformation von hefe.
DE69636890D1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
IT1153265B (it) Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi
DE3854840D1 (de) Rekombinant-mykobakterielle impfstoffe
PT85977A (en) Process for the preparation of human apolipoprotein ai and their variant forms by recombinant dna methods
IL70776A (en) Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
DE68914397D1 (de) Menschliches Lymphotoxin.
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
DK43991A (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
DE3876227D1 (de) Malaria-spezifische dna-sequenzen, ihre expressionsprodukte und deren verwendung.
KR920009847A (ko) 트롬빈 결합성 물질 및 그의 제조방법
DK56995A (da) Rekombinante lymphotoxin-varianter
MX9709846A (es) Secuencias de acidos nucleico y aminoacidos relacionados con el helicobacter pylori para procedimientos de diagnostico y terapeuticos.
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties